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ABSTRACT: Mitomycin C (MC) is a cytotoxic and mutagenic
antitumor agent that alkylates DNA upon reductive activation.
2,7-Diaminomitosene (2,7-DAM) is a major metabolite of MC in
tumor cells, which also alkylates DNA. MC forms seven DNA
adducts, including monoadducts and inter- and intrastrand cross-
links, whereas 2,7-DAM forms two monoadducts. Herein, the
biological effects of the dG-N2 adducts formed by MC and 2,7-
DAM have been compared by constructing single-stranded
plasmids containing these adducts and replicating them in
human embryonic kidney 293T cells. Translesion synthesis
(TLS) efficiencies of dG-N2-MC and dG-N2-2,7-DAM were 38
± 3 and 27 ± 3%, respectively, compared to that of a control
plasmid. This indicates that both adducts block DNA synthesis
and that dG-N2-2,7-DAM is a stronger replication block than dG-
N2-MC. TLS of each adducted construct was reduced upon siRNA knockdown of pol η, pol κ, or pol ζ. For both adducts, the
most significant reduction occurred with knockdown of pol κ, which suggests that pol κ plays a major role in TLS of these dG-N2
adducts. Analysis of the progeny showed that both adducts were mutagenic, and the mutation frequencies (MF) of dG-N2-MC
and dG-N2-2,7-DAM were 18 ± 3 and 10 ± 1%, respectively. For both adducts, the major type of mutation was G → T
transversions. Knockdown of pol η and pol ζ reduced the MF of dG-N2-MC and dG-N2-2,7-DAM, whereas knockdown of pol κ
increased the MF of these adducts. This suggests that pol κ predominantly carries out error-free TLS, whereas pol η and pol ζ are
involved in error-prone TLS. The largest reduction in MF by 78 and 80%, respectively, for dG-N2-MC and dG-N2-2,7-DAM
constructs occurred when pol η, pol ζ, and Rev1 were simultaneously knocked down. This result strongly suggests that, unlike
pol κ, these three TLS polymerases cooperatively perform the error-prone TLS of these adducts.
■ INTRODUCTION
Mitomycin C (MC) is the most studied member of a group of
potent antibiotics (reviewed recently in ref 1), discovered in
Japan in the 1950s, produced by the microorganism
Streptomyces caespitosus.2,3 MC has been widely used in cancer
chemotherapy.4 The anticancer activity of MC has been
postulated to be due to its DNA alkylation activity and,
notably, its ability to form interstrand DNA−DNA cross-
links.5,6 MC (structure shown in Scheme 1) possesses two
alkylating centers: the 1,2-aziridine and 10-carbamate groups.
MC is quite unreactive in its native state, but reductive
activation of the quinone moiety initiates its DNA alkylation
and antitumor activity.7,8 Like MC, 10-decarbamoyl mitomycin
C (DMC), the derivative obtained after chemical removal of
the 10-carbamoyl group (Scheme 1), is highly toxic and a
potent alkylating agent, despite lacking its carbamate group.9−11
Formation of DNA adducts by MC and DMC has been studied
in EMT6 mouse mammary tumor cells, Fanconi anemia-A cells,
normal human fibroblasts, and MCF-7 human breast cancer
cells.11,12 Nine different covalent DNA adducts, including six
monofunctional adducts and three cross-links, have been
isolated from cancer cells treated with MC.12 Seven of these
adducts are derived directly from MC (and DMC), in which
the covalent linkage is formed at the exocyclic amino group of
2′-deoxyguanosine (dG) in DNA. These adducts include a set
of two stereoisomeric monoadducts at the C1 position of MC
and DMC, plus two stereoisomeric interstrand cross-links
(ICL) and one intrastrand cross-link. The other two DNA
adducts are formed at the N7 and 2-amino group of dG with
2,7-diaminomitosene (2,7-DAM), the major metabolite of MC.
Isolation and characterization of these adducts were primarily
carried out in Maria Tomasz’s laboratory over a period of 15
years (1986−2000) (reviewed in refs 13 and 14). The first
DNA adduct of MC to be isolated and identified was
monoadduct 1 containing an α-linkage at the 1 position of
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MC with the exocyclic amino group of dG (Scheme 1).15,16
DMC forms the analogous monoadduct with a β-linkage, an
epimer of 2.11 Both MC and DMC form an ICL, 3, which
contains an additional covalent bond between the C10 of MC
and the exocyclic N2 position of dG in the complementary
strand.11,17 Not shown in Scheme 1 are the three epimers of
adducts 1−3, which contain a β-linkage to dG at the C1
position of MC (or DMC). Epimers of 2 and 3 are formed at a
high level by DMC.11 An intrastrand cross-link, 4, has also been
isolated.18 The structures of the two dG adducts of 2,7-DAM, 5
and 6, are shown in Scheme 1.19,20
In various tumor cell lines, 2,7-DAM is either nontoxic or
barely cytotoxic, whereas both MC and DMC are highly
cytotoxic (reviewed in ref 21). Surprisingly, DMC is somewhat
more cytotoxic than MC in cell cultures, but the level of ICL
formation seems to correlate with their cytotoxicity.11
Interestingly, DMC forms 20−30-fold more monoadducts
than MC, and its covalent bond formation to dG-N2 exhibits
opposite stereochemical preference to MC (i.e., MC forms
monoadduct 1, whereas DMC forms the epimer of 2).11,22,23
Although it is generally accepted that ICLs are largely
responsible for the cytotoxicity of MC and DMC, the repair
and replication of the various monoadducts are also of
significant interest to determine if they might be responsible
for generating secondary tumors. MC is mutagenic in bacterial
and mammalian cells.24,25 However, a convincing link between
specific DNA adducts formed by MC and its mutagenesis has
not been established. Monoadduct 1 is cytotoxic but not
mutagenic in Escherichia coli.26 In vitro studies of monoadducts
1 and 2 by several prokaryotic DNA polymerases showed that
Scheme 1. Chemical Structures of MC, DMC, and 2,7-DAM and Their Major DNA Adductsa
aNot shown are the three epimers of adducts 1−3, which contain a β-linkage to dG at the C1 position of MC. Epimers of adducts 2 and 3 are
formed at a high level by DMC.
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they are strong blocks of replication.27,28 In each case,
replication stopped at the base 3′ of the adduct site. Even
with the bypass polymerase human DNA polymerase η (hpol
η), no further extension was observed. In contrast, for 2,7-DAM
adduct 5, full-length extension of a primer by Klenow (exo-)
and T7 (exo-) DNA polymerases and partial extension by hpol
η were observed.28 Adducts 1 and 5 were also compared in vivo
in E. coli cells, which showed that MC adduct 1 is highly toxic
and reduces viability of the construct by nearly 90% even with
SOS, whereas 2,7-DAM adduct 5 decreased the viability by
∼50%.28 However, neither adduct was found to be mutagenic
in E. coli.28 Adduct 5, in addition, failed to induce mutations in
simian kidney cells.28
In the current work, we have compared the mutagenicity of
MC-derived monoadduct 1 and 2,7-DAM-derived adduct 6,
both at the N2 position of dG, in human embryonic kidney
(HEK) 293T cells. Both adducts block replication, but adduct 6
is a stronger block of replication than adduct 1. For the first
time, we also show that both adducts are mutagenic, inducing
primarily G → T mutations, and that adduct 1 is more
mutagenic than adduct 6. Employing an siRNA knockdown
approach, we also established that pol κ carries out
predominantly error-free translesion synthesis (TLS) of both
lesions, whereas pol η, pol ζ, and Rev1 are involved in error-
prone TLS.
■ EXPERIMENTAL PROCEDURES
Materials. dNTP solutions (100 mM) were purchased from New
England Biolabs (Ipswich, MA) or GE Healthcare (formerly
Amersham Biosciences, Piscataway, NJ). [γ-32P]ATP was purchased
from PerkinElmer (Waltham, MA). Unmodified oligonucleotides were
purchased from Midland Certified Reagents (Midland, TX).
siRNAs. Synthetic siRNA duplexes against PolH (SI02663619),
PolK (SI04930884), and Rev1 (SI00115311) and negative control
siRNA (1027280) were purchased from Qiagen (Valencia, CA),
whereas the same for Rev3 was purchased from Integrated DNA
Technologies (Coralville, IA). Sequences of all siRNAs have been
reported.29
Methods. 12-mer Containing a dG-N2-2,7-DAM Adduct. The
synthetic approach followed a postoligomerization method, as
reported in ref 30. Briefly, diethylamine (20 μL), DMSO (150 μL),
and the N2-(trimethylsilyl)ethoxycarbonyl-protected triaminomitosene
(6 mg, 0.015 mmol) were added to oligonucleotide 5′-CTAGTG(X)-
TATCC-3′ (with X = 2-fluoro-O6-(2-trimethylsilylethyl)-deoxyino-
sine; 204 nmol, 30 A260 units), and the mixture was stirred at room
temperature. The reaction was monitored by HPLC, which showed
that no starting material remained after 72 h, when the reaction was
stopped. The mixture was diluted with 750 μL of water and 100 μL of
3 M NaOAc (pH 5). Ethanol (3 mL) was added, and it was left at −20
°C for 20 min. The suspension was centrifuged (13 000 rpm for 15
min), and the supernatant was discarded. The brown residue was
washed twice with ethanol (750 μL), and the crude modified
oligonucleotide was dried in air. It was dissolved in a ZnBr2 solution
(300 μL, made by dissolving 250 mg of ZnBr2 in 150 μL of
nitromethane and 150 μL of isopropanol) and incubated at room
temperature for 48 h. It was quenched with EDTA (12 mL of a 0.05 M
solution), and the volume was reduced by one-half. The mixture was
subjected to Sephadex G-25 gel filtration, and the void fraction
containing the desired oligonucleotide was lyophilized and purified by
HPLC as described below.
12-mer Containing a dG-N2-MC Adduct. Oligonucleotide 5′-
CTAGTCGTATCC-3′ (676 nmol, 100 A260 units), the partially
complementary 7-mer 5′-TA(5meC)GACT-3′ (752 nmol, 63 A260
units, where 5meC represents the 5 methylated cytosine), and 48.9
μmole of mitomycin C were dissolved in phosphate buffer (5.8 mL of
0.1 mM buffer, pH 7.5). The solution was warmed to 55 °C for 5 min
with shaking. It was then slowly cooled to room temperature and left
at 4 °C for 30 min. A deaerated solution of Na2SO4 (22.3 μmole, 554
μL of a 40.2 mM solution in 0.1 M potassium phosphate buffer) was
added to the oligonucleotide mixture with continuous bubbling of
argon. The solution was stirred in air for 1.5 h, and then the solvents
were lyophilized. The mixture was diluted with 2.25 mL of water and
300 μL of 3 M NaOAc (pH 5). Ethanol (9 mL) was added, and the
mixture was left at −20 °C for 20 min. The suspension was centrifuged
(13 000 rpm for 15 min), and the supernatant was discarded. The
brown residue was washed twice with ethanol (2.25 mL), and the
desired adducted oligonucleotide was purified by HPLC as described
below.
Purification of Adducted Oligonucleotides. Adducted oligonucleo-
tides were purified by HPLC on a semiprep C-18 reverse-phase
column; the system was equipped with a diode array detector and
monitored at 260 and 320 nm (flow rate: 5 mL/min). The following
gradient was used for the oligonucleotide containing the dG-N2-2,7-
DAM adduct: initial conditions 99% NH4OAc (0.1 M in water)−1%
acetonitrile, then 60 min linear gradient to 80% acetonitrile, and 5 min
at 80% acetonitrile, followed by 5 min linear gradient to initial
conditions. The gradient used for the oligonucleotide containing the
dG-N2-MC adduct was as follows: buffer A: 0.1 M TEAA, 0.1 mM
EDTA; buffer B: 70% buffer A and 30% acetonitrile. Initial conditions:
25% buffer B, then 96 min linear gradient to 60% buffer B%, and 5 min
at 60% buffer B, followed by 5 min linear gradient to initial conditions.
Characterization of Adducted Oligonucleotides. A part of the
adducted oligonucleotides (containing dG-N2-2,7-DAM or dG-N2-2,7-
MC) was each dissolved (8.3 nmol, 1.3 A260 units) in the following
mixture: 700 μL of water, 200 μL of 0.5 M Tris-HCl, pH 8.6, and 350
μL of 0.025 M MgCl2 and incubated with snake venom
phosphodiesterase (4 units) and alkaline phosphatase (4 units) at
room temperature for 8 h. The mixtures were analyzed by reverse-
phase HPLC using the following gradient: 5−60% buffer B in buffer A
in 75 min (buffer A: 0.3 M potassium phosphate, pH 5.8; buffer B:
70% buffer A, 30% acetonitrile). The modified nucleosides (dG-N2-
2,7-DAM and dG-N2-MC) were identified by comparison with an
authentic sample on the basis of their retention times and UV spectra.
The adducted oligonucleotides also were subjected to ESI-MS analysis.
The m/z of dG-N2-MC-12-mer gave 3898.4 Da (negative electrospray;
deconvolution), which is 302 Da higher than the calculated mass of the
unmodified 12-mer (3596.4 Da), indicating the presence of MC
(334.3 Da) (minus OCH3 and H) in the 12-mer template. The dG-N
2-
2,7-DAM-12-mer gave m/z 3877.7 Da, which is 241.3 Da higher than
the unmodified 12-mer (3636.4 Da), indicating the presence of 2,7-
DAM moiety in the 12-mer. The purity of the adducted
oligonucleotides was examined by electrophoresis on a 16%
polyacrylamide gel containing 8 M urea (Figure S1), which showed
that the adducted 12-mers ran slightly slower than the unmodified 12-
mers and that they were >98% pure.
Construction of a pMS2 Vector Containing a Single dG-N2-2,7-
DAM or dG-N2-MC and Their Replication in HEK 293T Cells. We
have constructed a single adduct-modified single-stranded vector,
pMS2, with neomycin and ampicillin resistance genes, similarly as
reported elsewhere.31,32 The ligation efficiency of the adducted
oligonucleotides to both sides of the gapped pMS2 plasmid was in
excess of 60%. The HEK 293T cells were grown to ∼90% confluence
and transfected with 50 ng of construct in 6 μL of Lipofectamine
cationic lipid reagent (Invitrogen, Carlsbad, CA). Following trans-
fection with modified or unmodified pMS2, the cells were allowed to
grow at 37 °C in 5% CO2 for 24 h and the plasmid DNA was collected
and purified.33 It was used to transform E. coli DH10B, and
transformants were analyzed by oligonucleotide hybridization followed
by DNA sequence analysis.32,34
TLS Assay in Human Cells. The adduct-containing or control pMS2
construct was mixed with an equal amount of a single-stranded pMS2
DNA containing a different 12-mer sequence (i.e., 5′-GTGCG-
TGTTTGT-3′ in place of 5′-CTAGTGGTATCC-3′ or 5′-CTAGTC-
GTATCC-3′) constructed in a manner similar to the construction of
the dG-N2-2,7-DAM or dG-N2-MC (or control) construct. The mixed
DNA was used to transfect HEK 293T cells and processed as
described above. Oligonucleotide probes for the complementary
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sequences for both the wild-type and mutant (i.e., containing a
different 12-mer sequence) plasmids were used to analyze the progeny.
The mutant DNA was used as an internal control, and it gave equal
number of progeny as the control construct.
Mutational Analyses of TLS Products from Human Cells with
Polymerase Knockdowns. Prior to transfection of the control and dG-
N2-2,7-DAM- or dG-N2-MC-containing vectors, synthetic siRNA
duplexes were transfected into HEK 293T cells using Lipofectamine.
HEK 293T cells were plated in 6-well plates at 50% confluence. After a
24 h incubation, they were transfected with 100 pmole of siRNA
duplex mixed with Lipofectamine, diluted in Opti-MEM (Gibco), per
well. One day before transfection of the plasmid, cells were seeded in
24-well plates at 70% confluence. Cells were then cotransfected with
another aliquot of siRNA and either control plasmid or lesion-
containing plasmid at a ratio of 2:1. After a 24 h incubation, progeny
plasmids were isolated as described.
RT-PCR Analysis and Western blotting. Total RNA was extracted
from the cells 72 h after the first transfection of siRNA duplexes, and
100 ng of total RNA was used for RT-PCR analysis. Using primers
specific to TLS DNA polymerases and GAPDH as the control gene,
siRNA knockdown efficiency was determined as previously
described.29,35 Reverse transcription and the initial activation step of
the PCR were performed for 30 min at 50 °C and 15 min at 95 °C,
respectively. Details of the amplification of PolH, PolK, PolI, and Rev1
as well as GAPDH are described in detail in ref 29. RT-PCR products
were analyzed on a 2% agarose gel run at 100 V for 3 h in 1× TBE
buffer.
The specifics of the western blotting procedure have been reported
in ref 29. Briefly, cells were washed with cold phosphate buffered saline
and lysed in ice-cold RIPA buffer containing protease inhibitor
cocktail. After a 1 h incubation on ice, the mixture was centrifuged at
10 000 rpm for 15 min at 4 °C, the protein concentration was
determined, and western blotting was performed on the supernatant.
The protein extracts were boiled in sample loading buffer. Proteins
were separated on either a 5 or 7% SDS-PAGE gel by electrophoresis
for 2 h and transferred onto PVDF membranes. The membranes were
blocked with 5% milk and incubated with antibodies that specifically
recognize human PolH, PolK, PolI, Rev3, or Rev1. Human β-actin
antibody was used to confirm equal gel loading. Horseradish
peroxidase-conjugated goat anti-rabbit and goat anti-mouse secondary
antibodies were used at 1:5000 dilutions. The signals were developed
using Pierce ECL western blotting substrate, and images were taken
using a PhosphorImager.
■ RESULTS
dG-N2-MC and dG-N2-2,7-DAM Are Replication-Block-
ing Lesions in HEK 293T Cells. Each dG-N2 adduct construct
and an unmodified plasmid (as an internal control) were
cotransfected into HEK 293T cells. Following a 24 h incubation
to allow for the replication of the plasmids, the progeny DNA
was isolated and used to transform E. coli DH10B cells. The
fractions of the colonies originating from the adduct-containing
plasmid relative to the unmodified plasmid, which indicates the
TLS efficiency, were determined by oligonucleotide hybrid-
ization. As shown in Figure 1, compared to the unmodified
plasmid, TLS efficiencies of dG-N2-MC and dG-N2-2,7-DAM
were 38 ± 3 and 27 ± 3%, respectively. This indicates that both
adducts block DNA synthesis and that dG-N2-2,7-DAM is a
stronger replication block compared to that of dG-N2-MC.
Roles of pol η, pol κ, pol ζ, and Rev1 in TLS Efficiency
of dG-N2-MC and dG-N2-2,7-DAM. In order to define the
replication-blocking characteristics of these dG-N2 adducts and
identify the polymerases involved in their bypass, we knocked
down several TLS polymerases prior to replicating the adduct-
containing plasmid in HEK 293T cells. Upon knockdown of
pol η, pol κ, or pol ζ, TLS of each construct containing the MC
or 2,7-DAM adduct was reduced. For dG-N2-MC, knockdown
of pol η, pol κ, or pol ζ, respectively, resulted in 12, 48, or 35%
reduction in TLS. For dG-N2-2,7-DAM, the trend was similar,
and knockdown of pol η, pol κ, or pol ζ, respectively, resulted
in 15, 37, or 30% reduction in TLS. Evidently, in each case, the
most significant reduction occurred with knockdown of pol κ,
which suggests that pol κ plays a major role in TLS of these
adducts. Further reduction in TLS was observed upon
simultaneous knockdown of two or three TLS polymerases.
Simultaneous knockdown of pol η, pol ζ, and Rev1, for
example, resulted in 68 and 63% reductions in TLS for the dG-
N2-MC and dG-N2-2,7-DAM constructs, respectively. Gen-
erally, the trend of reduced TLS with knockdowns followed an
analogous trend in dG-N2-MC and dG-N2-2,7-DAM constructs,
although the extent of reduction in TLS was more pronounced
in the case of the former.
Mutagenicity of dG-N2-MC and dG-N2-2,7-DAM in HEK
293T Cells and the Roles of TLS Polymerases. While dG-
N2-2,7-DAM was a stronger block to replication than dG-N2-
MC, the latter was found to be more mutagenic than the
former in HEK 293T cells (Figure 2). The mutation
frequencies of dG-N2-MC (adduct 1) and dG-N2-2,7-DAM
(adduct 6) were 18 ± 3 and 10 ± 1%, respectively. For both
adducts, the major type of mutation was G → T, which
occurred in 12 and 6% frequencies in dG-N2-MC and dG-N2-
2,7-DAM, respectively. They also induced G → A (∼3% for
each adduct) and low levels of G → C and semitargeted
mutations (Table S2A). Knockdown of pol η and pol ζ reduced
the MF of dG-N2-MC and dG-N2-2,7-DAM, whereas knock-
down of pol κ increased the MF of these adducts. MFs of dG-
N2-MC and dG-N2-2,7-DAM constructs were reduced by 44
and 20%, respectively, upon knockdown of pol η, whereas
reductions by 33 and 11% of the same was observed when pol ζ
was knocked down (Figure 2 and Table S2B,D). In contrast,
MF of dG-N2-MC and dG-N2-2,7-DAM constructs was
Figure 1. Effect of siRNA knockdown of TLS polymerases on the
extent of replicative bypass of dG-N2-MC (in 5′-CTAGTCG*-
TATCC-3′) and dG-N2-2,7-DAM (in 5′-CTAGTGG*TATCC-3′).
Percent TLS in various polymerase knockdowns was measured using
an internal control of unmodified plasmid in which a different 12-mer
was ligated. The data represent the mean and standard deviation of
results from two independent experiments. HEK 293T cells were
treated with negative control (NC) siRNA (WT), whereas the other
single, double, or triple polymerase knockdowns are indicated above
the bar. TLS result from each knockdown experiment was considered
statistically significant (p < 0.02) (except in pol η-knockdown cells)
compared to that from HEK 293T cells treated with NC siRNA (WT).
The p value of %TLS for each knockdown was calculated using a two-
tailed, unpaired Student’s t test.
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increased by 39 and 50%, respectively, when pol κ was knocked
down (Figure 2 and Table S2C). This suggests that pol κ
predominantly carries out error-free TLS, whereas pol η and
pol ζ are involved in error-prone TLS of these two dG-N2
adducts. We also investigated the MF when pol η and pol ζ
were simultaneously knocked down, which exhibited a synergy
in reducing the MF (by 56 and 60%, respectively, for dG-N2-
MC and dG-N2-2,7-DAM constructs) (Figure 2 and Table
S2E). The largest reduction in MF, 78 and 80% for dG-N2-MC
and dG-N2-2,7-DAM constructs, respectively, was observed
when pol η, pol ζ, and Rev1 were simultaneously knocked
down (Figure 2 and Table S2F). This result suggests that these
three TLS polymerases cooperatively perform error-prone TLS
of these adducts.
■ DISCUSSION
Our result that dG-N2-2,7-DAM is a stronger replication block
than dG-N2-MC is interesting since it was reported that 2,7-
DAM is not cytotoxic and does not activate the p53 pathway,
whereas MC and DMC are cytotoxic and activate the p53
pathway.36,37 However, the lack of substantial cytotoxicity of
2,7-DAM was attributed to its inability to form cross-links in
DNA, which is considered to be the hallmark of MC’s ability to
kill malignant cells.6,13,21 Of the various monoadducts of MC
and 2,7-DAM, in an earlier work in E. coli, we found that dG-
N2-MC is more toxic than dG-N7-2,7-DAM, with the latter
being the other monoadduct (structure 5 in Scheme 1) formed
by 2,7-DAM.28 In addition, dG-N2-MC was found to be a
complete block to pol η in vitro, and replication stopped one
nucleotide before the adduct, whereas pol η carried out primer
extension to full-length product past dG-N7-2,7-DAM.28
However, TLS of dG-N2-MC and dG-N2-2,7-DAM was not
compared in any prior study, and the current investigation is
the first to show that dG-N2-2,7-DAM is a stronger block to
replication than dG-N2-MC in HEK 293T cells. It should be
noted, however, that the 5′ base of the two adducts is not
identical. The 5′ base of dG-N2-MC is C, whereas dG-N2-2,7-
DAM has a 5′ G. It is unclear if this difference in the 5′ base has
any effect on the TLS and MF of the two adducts.
A high-resolution NMR solution structure of dG-N7-2,7-
DAM in duplex DNA indicated that the drug moiety is not
intercalated and lies in the major groove of a relatively
unperturbed B-DNA structure.38 In contrast, the MC moiety of
the dG-N2-MC lies tightly in the slightly widened minor groove
of duplex B-DNA,39 but there are extensive noncovalent
contacts between the drug and the minor groove of the DNA
duplex. Structural information on the dG-N2-2,7-DAM is
lacking, but it is conceivable that it occupies the minor groove
in a manner similar to that of the dG-N2-MC adduct. It was
proposed that DNA adducts localized in the solvent-exposed
major groove (as in the case of dG-N7-2,7-DAM) are better
tolerated than adducts located in the minor groove (such as the
two adducts used in this study) that interact with the
polymerase surface.40 This suggestion is consistent with the
results that show efficient replication past dG-N7-2,7-DAM,
whereas both dG-N2-2,7-DAM and dG-N2-MC are strong
blocks of DNA synthesis.
In view of the result that dG-N2-MC is significantly
mutagenic in HEK 293T cells, another intriguing question is
why it is not mutagenic in E. coli, even though in a uvrA strain
∼0.2% semitargeted mutants were detected.26 We believe that
the rationalization for this apparent discrepancy lies in the
abundance of TLS polymerases, which allows for a much higher
level of TLS in human cells compared to that in E. coli, and the
identity of the polymerases that bypass it. TLS of the dG-N2-
MC construct in E. coli was reported to be ∼7%, which
increased 2-fold with SOS,26 in comparison to 38% TLS in
HEK 293T cells, as determined in the current work. Structural
studies of a replication-blocking benzo[a]pyrene-dG-N2 adduct
indicate that the steric constraints of the active site of a high-
fidelity DNA polymerase result in structural disruptions that are
incompatible with DNA replication of this type of bulky dG-N2
adduct.40 Accordingly, we hypothesize that replicative poly-
merases, such as DNA polymerase III in E. coli and pol δ and ε
in human cells, cannot bypass this adduct and that only the
TLS polymerases are able to carry out TLS. It also appears that
the TLS polymerases in human cells, with the exception of pol
κ, though more efficient in TLS of this adduct, are also more
error-prone. However, of the three TLS polymerases in E. coli,
the identity of the polymerase responsible for TLS of dG-N2-
MC (and dG-N2-2,7-DAM) is yet to be determined, but this
polymerase is less error-prone in comparison to the
coordinated TLS carried out by pol η, pol ζ, and Rev1.
Despite the difference in magnitude, the nearly identical
pattern of TLS and mutagenesis data for replication past dG-
N2-MC and dG-N2-2,7-DAM in this work strongly suggests that
the mechanism of error-free and error-prone bypass of these
two adducts are the same. Of the four human Y family DNA
polymerases, pol κ is the only enzyme that has homologues in
prokaryotes and archaea, such as DinB (pol IV) in E. coli and
Dbh and Dpo4 in Sulfolobus solfataricus. However, pol κ is set
apart from pol IV, Dpo4, and the others by an extension at its
N-terminus, which is conserved only in eukaryotes and is
critical for pol κ’s activity in lesion bypass and mispair
extension.41 Even when pol κ is inefficient at inserting a base
opposite certain DNA lesions, it efficiently carries out extension
after another polymerase incorporates a base opposite the DNA
adduct.42 Specifically, for dG-N2 adducts, however, pol κ
promotes both error-free insertion and extension efficiently.43
The finding that pol κ performs error-free TLS of the MC and
2,7-DAM adducts is indeed consistent with a substantial body
of work that established pol κ’s role in accurate and efficient
replication past many dG-N2 adducts, including the major dG-
N2 adduct of benzo[a]pyrene.43−45 The active site of pol κ is
Figure 2. Mutational frequency of dG-N2-MC (in 5′-CTAGTCG*-
TATCC-3′) and dG-N2-2,7-DAM (in 5′-CTAGTGG*TATCC-3′) in
HEK 293T cells cotransfected with NC siRNA (WT) or siRNA for
single, double, or triple polymerase knockdowns (shown above the
bar). The data represent the average of two independent experiments
(shown in Table S2A−F).
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more open at the minor groove side of the DNA template
compared to that of other Y family polymerases, which allows it
to accommodate a bulky dG-N2 adduct in its anti conformation
to base-pair with C and continue error-free replication.46 The
extension at the N-terminus, known as the N-clasp of human
pol κ, plays a crucial role in stabilizing the single-stranded
template and interacting with all three (i.e., finger/thumb/little
finger) DNA binding domains.45,46 As shown in Figure 1, pol κ
appears to be responsible for a major fraction of TLS of the two
MC and 2,7-DAM dG-N2 adducts. A large increase in the
mutation frequency in the absence of pol κ underscores its
ability to perform accurate TLS (Figure 2). In contrast, pol η,
pol ζ, and Rev1 together are responsible for the major fraction
of mutagenic TLS (Figure 2). On the basis of the current state
of knowledge regarding TLS,47−49 we postulate that pol η
incorporates the wrong base (predominantly A) opposite the
dG-N2 adduct of MC or 2,7-DAM, which is extended by pol ζ,
whereas Rev1 performs a noncatalytic role by physically
interacting with the other two polymerases. Additional in
vitro and cellular experiments may be able to test this
hypothesis in the future.
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